What is the current KRAS Tests market size?

The KRAS Tests market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the KRAS Tests market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the KRAS Tests market?

Key drivers include rising cancer incidence and advancements in genetic testing technologies.

What are the major challenges facing the KRAS Tests market?

Challenges include high development costs and regulatory hurdles.

Which regions are leading the KRAS Tests market?

North America and Europe are currently leading the market due to strong healthcare infrastructure.

Who are the top companies in the KRAS Tests market?

Top companies include Illumina, Thermo Fisher, and Roche, offering innovative testing solutions.

What future opportunities exist in the KRAS Tests market?

Future opportunities include expanding into emerging markets and developing new testing technologies.

How is technology impacting the KRAS Tests market?

Advances in next-generation sequencing are improving test accuracy and driving market growth.

What is the current regulatory landscape for the KRAS Tests market?

The regulatory landscape is evolving, with increasing focus on precision medicine and genetic testing standards.

What is the future outlook for the KRAS Tests market?

The future outlook is positive, with growing demand for genetic testing and advancements in technology.

What Is the Global KRAS Tests Market Worth in 2026?

KRAS Tests by Application (Colorectal Cancer (CRC), Lung Cancer), by Types (KRAS Sanger sequencing Tests, KRAS Nucleic Acid Amplification Tests (NAAT), KRAS Other Tests), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

KRAS Tests Market Size | CAGR 10.2 Forecast 2033

What Is the Global KRAS Tests Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

KRAS Tests Market Overview

The KRAS Tests market refers to the industry that provides diagnostic tests for detecting KRAS gene mutations, which are commonly found in various types of cancer. As the global healthcare landscape continues to evolve, the KRAS Tests market size is estimated to be around $1.3 billion, with a growth outlook that is expected to drive the market forecast towards significant expansion. The industry expansion is anticipated to be fueled by increasing demand for personalized medicine, advancements in molecular diagnostics, and a growing need for precision oncology. The scope of the KRAS Tests market encompasses various types of tests, including PCR, sequencing, and immunohistochemistry, which are used in different applications such as lung cancer, colorectal cancer, and pancreatic cancer diagnosis.

Loading chart…

The KRAS Tests market is expected to grow at a CAGR of 10.5% during the forecast period, driven by macro drivers such as increasing cancer incidence, advancements in genomic analysis, and growing adoption of precision medicine. Key forces shaping the industry include technology shifts towards non-invasive testing, regulatory approvals for new diagnostic tests, and competitive intensity among market players. The largest region for the KRAS Tests market is North America, while the fastest-growing region is expected to be Asia Pacific, driven by increasing demand for cancer diagnostics and growing investments in healthcare infrastructure. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends and developments in the KRAS Tests market.

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	2.68 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Qiagen NV; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc; Takara Bio Inc; Panagene Inc; Amoy Diagnostics Co Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The KRAS Tests market is witnessing significant growth, driven by increasing demand for precision medicine and targeted therapies. The KRAS Tests market size is expected to expand substantially during the forecast period, with a growth forecast that indicates a promising future for industry players.

Growth Drivers2 items

Advances in next-generation sequencing technologies have improved the accuracy and speed of KRAS mutation detection, driving adoption in clinical settings

Rising prevalence of cancer and the need for early diagnosis and treatment are fueling the demand for KRAS tests, contributing to market growth

Restraints2 items

High development costs associated with KRAS tests and the need for specialized equipment and expertise may limit accessibility in resource-constrained settings

Stringent regulatory requirements and the need for rigorous testing and validation may slow the introduction of new KRAS tests to the market

Opportunities2 items

Emerging liquid biopsy technologies offer a promising opportunity for non-invasive KRAS mutation detection, expanding the potential market for KRAS tests

Increasing collaboration between industry players and research institutions may accelerate the development of new KRAS tests and drive innovation in the market

Challenges2 items

The KRAS Tests market is highly competitive, with multiple players offering similar products, making it challenging for companies to differentiate themselves and gain market share

Reimbursement and pricing pressures may impact the profitability of KRAS tests, particularly in markets with stringent healthcare budgets and cost-containment measures

Market Segmentation

Loading chart…

The KRAS Tests market can be segmented based on Application, which includes subtypes such as lung cancer, colorectal cancer, and other cancers. This segmentation contributes to the overall KRAS Tests market size by providing insights into the specific uses of KRAS tests. Understanding the application segment is crucial for market players to develop targeted strategies and products. The KRAS Tests segmentation by application helps in identifying the most prominent areas of use, driving the market growth.

Another significant segmentation of the KRAS Tests market is by Types, which comprises subtypes such as KRAS mutation tests and KRAS expression tests. This segmentation category plays a vital role in determining the overall market size by highlighting the different types of tests available. The market taxonomy of KRAS tests by types enables market players to understand the competitive landscape and develop innovative products. By analyzing the types segment, market players can identify opportunities for growth and expansion.

KRAS Tests Segmentation Breakdown7 items

Application

Colorectal Cancer (CRC)

Lung Cancer

Types

KRAS Sanger sequencing Tests

KRAS Nucleic Acid Amplification Tests (NAAT)

KRAS Other Tests

Regional Insights

Loading chart…

The KRAS Tests market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of KRAS tests, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: North America - ecosystem maturity, high demographics of cancer patients, and advanced infrastructure; Europe - increasing adoption of liquid biopsies, favorable policies, and rising investments in research and development; Asia Pacific - growing demand for cancer diagnostics, improving infrastructure, and expanding ecosystem; Latin America - increasing awareness of cancer diagnostics, rising investments in healthcare, and growing demand for KRAS tests; and Middle East & Africa - rising demand for cancer diagnostics, growing investments in healthcare infrastructure, and increasing adoption of KRAS tests.

The regional forecast indicates a significant growth opportunity in the KRAS Tests market, driven by increasing demand for cancer diagnostics and growing adoption of KRAS tests across regions. The market is expected to witness a significant shift towards Asia Pacific, driven by the region's large patient population, growing ecosystem, and rising investments in healthcare infrastructure.

Competitive Landscape

The KRAS Tests market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The KRAS Tests competitive landscape is driven by the ability of companies to differentiate themselves through innovative products, strong distribution networks, and strategic partnerships. Key players are focusing on leveraging these competitive levers to gain market share.

Companies in the KRAS Tests market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies need to focus on technology, service model, channel strength, customization, and cost advantages. The following companies are notable for their strategic focus:

Qiagen NV: regional expansion

F. Hoffmann-La Roche Ltd: innovation pipeline

Thermo Fisher Scientific Inc: vertical integration

Takara Bio Inc: premium pricing

Panagene Inc: OEM tie-ups

Amoy Diagnostics Co Ltd: local manufacturing

Key KRAS Tests Companies6 items

Qiagen NV

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific Inc

Takara Bio Inc

Panagene Inc

Amoy Diagnostics Co Ltd

Market Ecosystem

The KRAS Tests ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development and supply of KRAS test kits, integration with laboratory systems, and delivery of diagnostic services to healthcare providers and patients. Understanding the KRAS Tests ecosystem is crucial for conducting a comprehensive value chain analysis.

Raw material suppliers — provide reagents and components

Technology providers — develop KRAS test kits and platforms

OEMs/manufacturers — produce diagnostic equipment and instruments

System integrators/EPCs — integrate KRAS tests with laboratory systems

Distributors/channel partners — supply KRAS test kits to laboratories and hospitals

Service providers/after-sales — offer maintenance and support services

Regulators/standards bodies — establish guidelines and approvals for KRAS tests

In the KRAS Tests ecosystem, control points are primarily held by regulators and standards bodies, who influence adoption through approvals and guidelines. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, which can impact the development and supply of KRAS test kits. Switching costs and partnerships are also significant, as laboratories and hospitals may be locked into specific platforms or suppliers, and interoperability requirements can limit the flexibility of KRAS test integration. The ecosystem differs by region, with varying regulatory frameworks and market dynamics influencing the adoption and delivery of KRAS tests.

Recent Industry Insights

The KRAS Tests industry trends have witnessed significant developments over the last 12-18 months, driven by advancements in technology and shifting consumer demands. Recently, there have been notable partnerships between leading pharmaceutical companies and diagnostic firms, aimed at developing more accurate and efficient KRAS testing solutions. Additionally, the industry has seen a surge in product launches, with several companies introducing innovative testing kits and platforms.

Furthermore, the KRAS Tests market has experienced a rise in funding rounds and expansions, with investors showing increased interest in the potential of KRAS testing for cancer diagnosis and treatment. Regulatory changes have also played a crucial role in shaping the industry, with authorities implementing new guidelines and standards for KRAS testing. As the industry continues to evolve, it is essential to stay informed about the latest KRAS Tests industry trends and developments to remain competitive.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the KRAS Tests market outlook. The market attractiveness is moderate, driven by increasing demand for targeted therapies in cancer treatment. The competitive intensity is high, with several major players investing in research and development. The long-term outlook is promising, with potential applications in various cancer types. The innovation landscape is rapidly evolving, with advancements in next-generation sequencing and liquid biopsy technologies.

The demand–supply balance is expected to be stable, with key players expanding their production capacities. However, key risk factors include regulatory challenges, reimbursement issues, and intense competition. Overall, the KRAS Tests market is poised for growth, driven by advances in technology and increasing adoption of personalized medicine.

11 items

1. Executive Summary

2. KRAS Tests Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global KRAS Tests Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global KRAS Tests Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Colorectal Cancer (CRC)

6.1.2. Lung Cancer

6.2. Global KRAS Tests Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. KRAS Sanger sequencing Tests

6.2.2. KRAS Nucleic Acid Amplification Tests (NAAT)

6.2.3. KRAS Other Tests

6.3. Global KRAS Tests Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global KRAS Tests Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global KRAS Tests Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global KRAS Tests Market Competition by Key Manufacturers

8.1. Global KRAS Tests Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global KRAS Tests: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Qiagen NV

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. F. Hoffmann-La Roche Ltd

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Thermo Fisher Scientific Inc

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Takara Bio Inc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Panagene Inc

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Amoy Diagnostics Co Ltd

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global KRAS Tests Market

Figure 4: Global KRAS Tests Market: Drivers

Figure 5: Global KRAS Tests Market: Challenges

Figure 6: Global KRAS Tests Market: Trends

Figure 7: Global KRAS Tests Market: Opportunity

Figure 8: Global KRAS Tests Market: Restraint

Figure 9: Global KRAS Tests Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global KRAS Tests Market Value (USD Million) By Region

Figure 15: Global KRAS Tests Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global KRAS Tests Market Value (USD Million) By Region

Figure 23: Global KRAS Tests Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global KRAS Tests Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global KRAS Tests Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global KRAS Tests Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global KRAS Tests Market Value (USD Million) By Region

Table 10: Global KRAS Tests Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global KRAS Tests Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global KRAS Tests Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global KRAS Tests Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Qiagen NV Basic Information And Sales Area

Table 31: Qiagen NV. Products Portfolio

Table 32: F. Hoffmann-La Roche Ltd Basic Information And Sales Area

Table 33: F. Hoffmann-La Roche Ltd. Products Portfolio

Table 34: Thermo Fisher Scientific Inc Basic Information And Sales Area

Table 35: Thermo Fisher Scientific Inc. Products Portfolio

Table 36: Takara Bio Inc Basic Information And Sales Area

Table 37: Takara Bio Inc. Products Portfolio

Table 38: Panagene Inc Basic Information And Sales Area

Table 39: Panagene Inc. Products Portfolio

Table 40: Amoy Diagnostics Co Ltd Basic Information And Sales Area

Table 41: Amoy Diagnostics Co Ltd. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global KRAS Tests Market Value (USD Million) By Region

Table 47: Global KRAS Tests Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

KRAS Tests Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	2.68 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Qiagen NV; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc; Takara Bio Inc; Panagene Inc; Amoy Diagnostics Co Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options